



September 27, 2013

CyberAgent Inc. – Ratio Change and Stock Distribution

DR CUSIP: 23248D105
DR ISIN: US23248D1054
DR Ticker Symbol: CYGIY

Please be advised that CyberAgent Inc. has announced a 100 for 1 stock split on its ordinary shares in the local market effective October 1, 2013. As a result, BNY Mellon will change the ratio on the CyberAgent Inc. ADR program. The ratio change will occur simultaneously with a 900% DS distribution (or 9 additional DSs for each 1 DS held).

Please note the following:

DR Record Date: October 7, 2013
DR Payable Date: October 8, 2013
DR Distribution Rate: 900% Distribution (or 9 additional DSs for each 1 DS held)
Old DR Ratio: 20 DR : 1 Common share
New DR Ratio: 2 DR : 1 Common share
Effective date for DR ratio change: October 9, 2013

An issuance fee of \$0.05 will be assessed.

Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon's books will be closed for all issuance and cancellation transactions from October 1, 2013 and will reopen on October 14, 2013.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
+1 212 815-2267
Adrdesk@bnymellon.com

London

Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

Hong Kong

Herston Powers
Vice President
+852 2 840 9868
herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers. This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.